Impact of prior treatment history on efficacy of Risankizumab compared with placebo in patients with moderate-to-severe plaque psoriasis: integrated analyses from three phase 3 trials

被引：0
|
作者：
Strober, B. [1 ,2 ]
Lambert, J. [3 ]
Gu, Y. [4 ]
Zhan, T. [4 ]
Thompson, E. Z. [5 ]
Valdecantos, W. C. [4 ]
Menter, A. [6 ]
机构：
[1] Univ Connecticut, Ctr Hlth, Farmington, CT USA
[2] Prob Med Res, Farmington, CT USA
[3] Ghent Univ Hosp, Dept Dermatol, Ghent, Belgium
[4] AbbVie Inc, N Chicago, IL USA
[5] AbbVie Inc, Redwood City, CA USA
[6] Baylor Univ, Med Ctr, Div Dermatol, Dallas, TX USA
来源：
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT | 2019年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P100
引用
收藏
页码：117 / 117
页数：1
相关论文
共 50 条
  • [21] RISANKIZUMAB EFFICACY/SAFETY IN MODERATE-TO-SEVERE PLAQUE PSORIASIS: 16-WEEK RESULTS FROM IMMHANCE
    Blauvelt, Andrew
    Papp, Kim A.
    Gooderham, Melinda
    Langley, Richard G.
    Leonardi, Craig
    Lacour, Jean-Philippe
    Philipp, Sandra
    Tyring, Stephen
    Bukhalo, Michael
    Wu, Jashin J.
    Bagel, Jerry
    Frankel, Ellen H.
    Pariser, David
    Flack, Mary
    Scherer, Joseph
    Geng, Ziqian
    Gu, Yihua
    Camez, Anne
    Thompson, Elizabeth H. Z.
    ACTA DERMATO-VENEREOLOGICA, 2018, 98 : 30 - 30
  • [22] Population Pharmacokinetics of Risankizumab in Healthy Volunteers and Subjects with Moderate to Severe Plaque Psoriasis: Integrated Analyses of Phase I–III Clinical Trials
    Ahmed A. Suleiman
    Mukul Minocha
    Amit Khatri
    Yinuo Pang
    Ahmed A. Othman
    Clinical Pharmacokinetics, 2019, 58 : 1309 - 1321
  • [23] High and durable clearance through 52 weeks of risankizumab treatment in patients with moderate-to-severe plaque psoriasis
    Gooderham, M.
    Lebwohl, M.
    Gordon, K.
    Wu, T.
    Photowala, H.
    Bachelez, H.
    EXPERIMENTAL DERMATOLOGY, 2023, 32 (04) : E30 - E31
  • [24] High and durable clearance through 52 weeks of risankizumab treatment in patients with moderate-to-severe plaque psoriasis
    Gooderham, M.
    Lebwohl, M.
    Gordon, K.
    Wu, T.
    Photowala, H.
    Bachelez, H.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2019, 33 : 20 - 20
  • [25] Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis: An integrated analysis of UltIMMa-1 and UltIMMa-2
    Lebwohl, Mark
    Bachelez, Herve
    Valdecantos, Wendell C.
    Wu, Tianshuang
    Gordon, Kenneth
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB199 - AB199
  • [26] Ixekizumab treatment and the impact on SF-36: results from three pivotal phase III randomised controlled trials in patients with moderate-to-severe plaque psoriasis
    Richard G. B. Langley
    Kristian Reich
    Vibeke Strand
    Steven R. Feldman
    Carle Paul
    Kenneth Gordon
    Richard B. Warren
    Darryl Toth
    Enkeleida Nikaï
    Baojin Zhu
    Orin Goldblum
    Emily Edson-Heredia
    Hilde Carlier
    Russel Burge
    Chen-Yen Lin
    Kristin Hollister
    Matthias Augustin
    Quality of Life Research, 2020, 29 : 369 - 380
  • [27] Ixekizumab treatment and the impact on SF-36: results from three pivotal phase III randomised controlled trials in patients with moderate-to-severe plaque psoriasis
    Langley, Richard G. B.
    Reich, Kristian
    Strand, Vibeke
    Feldman, Steven R.
    Paul, Carle
    Gordon, Kenneth
    Warren, Richard B.
    Toth, Darryl
    Nikai, Enkeleida
    Zhu, Baojin
    Goldblum, Orin
    Edson-Heredia, Emily
    Carlier, Hilde
    Burge, Russel
    Lin, Chen-Yen
    Hollister, Kristin
    Augustin, Matthias
    QUALITY OF LIFE RESEARCH, 2020, 29 (02) : 369 - 380
  • [28] Efficacy and safety of risankizumab in Japanese patients with moderate to severe plaque psoriasis: Results from the SustaIMM phase 2/3 trial
    Ohtsuki, Mamitaro
    Fujita, Hideki
    Watanabe, Mitsunori
    Suzaki, Keiko
    Flack, Mary
    Huang, Xin
    Kitamura, Susumu
    Valdes, Joaquin
    Igarashi, Atsuyuki
    JOURNAL OF DERMATOLOGY, 2019, 46 (08): : 686 - 694
  • [29] Impact of ixekizumab treatment on depressive symptoms: An integrated analysis of three phase 3 clinical studies in patients with moderate-to-severe psoriasis
    Griffiths, Christopher
    Fava, Maurizio
    Miller, Andrew
    Russell, James
    Ball, Susan
    Xu, Isabel
    Acharya, Nayan
    Rapaport, Mark
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB253 - AB253
  • [30] The effect of bodyweight on the efficacy and safety of ixekizumab: results from an integrated database of three randomised, controlled Phase 3 studies of patients with moderate-to-severe plaque psoriasis
    Reich, K.
    Puig, L.
    Mallbris, L.
    Zhang, L.
    Osuntokun, O.
    Leonardi, C.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2017, 31 (07) : 1196 - 1207
12345